Adults showing signs of memory loss and cognitive decline can now be screened for Alzheimer’s disease with a simple blood draw instead of a spinal tap or an expensive brain scan. The Food and Drug Administration cleared the Lumipulse G pTau217/beta-Amyloid 1-42 Plasma Ratio, made by Fujirebio Diagnostics, Inc., as the first blood-based diagnostic device authorized to help identify Alzheimer’s in symptomatic patients. The clearance arrived through the 510(k) pathway under record K242706, but a Class 2 device recall tied to the same product number raises questions about whether clinics and insurers will move quickly to adopt it.
Why a plasma Alzheimer’s test changes the diagnostic equation
Until now, confirming amyloid buildup in the brain required either a positron emission tomography scan or a cerebrospinal fluid draw obtained through lumbar puncture. Both procedures are costly, uncomfortable, and largely confined to specialty centers. A blood test that can be run in a primary care office removes those barriers for millions of older Americans whose cognitive symptoms go undiagnosed or are attributed to normal aging.
The Lumipulse plasma ratio test measures two proteins, phosphorylated tau 217 and beta-amyloid 1-42, whose relative levels in blood correlate with amyloid plaque deposits in the brain. Fujirebio already had a cerebrospinal-fluid version of the assay on the market, cleared through the FDA’s De Novo pathway. The new plasma test used that earlier device as its legally marketed predicate, allowing Fujirebio to pursue the faster 510(k) route rather than starting from scratch.
The practical result is that a doctor who suspects early Alzheimer’s can order the blood test, receive a ratio result, and use it alongside clinical evaluation to decide whether to refer the patient for further workup or begin treatment discussions. That shift from specialty-only confirmation to office-level screening could dramatically expand the number of patients who receive a timely diagnosis, especially in rural areas and community practices that lack access to PET scanners or lumbar puncture expertise.
A peer-reviewed study published in the journal Brain found that the pTau217/beta-amyloid 1-42 ratio improved accuracy and reduced uncertain results when compared with PET and CSF reference standards. Fewer indeterminate readings mean fewer patients left in diagnostic limbo, which matters both clinically and financially as new anti-amyloid therapies enter the market and require confirmed amyloid status before infusion.
Fujirebio’s 510(k) clearance and the recall that followed
The FDA’s press release described the device as the first blood-based in vitro diagnostic to aid in diagnosing Alzheimer’s disease. The official classification listed in the agency’s device database is “Immunoassay Blood Test For Amyloid Pathology Assessment,” and the applicant of record is Fujirebio Diagnostics, Inc., based on the 510(k) filing for K242706.
Yet the same K242706 number also appears in the FDA’s medical device recall database. A Class 2 recall notice covers certain lots of the Lumipulse G pTau217/beta-Amyloid 1-42 Plasma Ratio. Class 2 recalls involve situations where use of or exposure to a product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. No primary FDA or Fujirebio statements detailing the root cause or specific corrective actions for the affected lots are available in the public record reviewed for this report.
The overlap between a first-of-its-kind clearance and an active recall is not unprecedented in the device world, but it creates a concrete tension for health systems weighing adoption. Laboratories considering the test must verify that their reagent lots are not among those flagged, and compliance teams will want evidence of corrective action before scaling up orders. For insurers evaluating coverage, the recall introduces uncertainty about lot-to-lot consistency that post-market surveillance data will eventually need to resolve.
Open questions for clinicians, patients, and payers
Several gaps in the public record will shape how quickly this test reaches routine clinical use. No official pricing, billing codes, or Medicare coverage determinations tied to the plasma assay have been published in the sources reviewed. Without a clear reimbursement pathway, physician offices may hesitate to order the test routinely, especially in smaller practices that cannot absorb financial risk if claims are denied or underpaid.
Clinicians also face questions about where in the diagnostic algorithm to place the plasma assay. The FDA clearance specifies use in adults who already show signs or symptoms of mild cognitive impairment or dementia, not as a general screening tool for the broader population. That means physicians must still rely on history, cognitive testing, and differential diagnosis to decide who should be tested. How aggressively primary care clinicians adopt the assay may depend on specialty society guidelines that have not yet fully integrated this specific blood test.
Patients, meanwhile, may encounter uneven access. Large academic centers and integrated health systems with in-house laboratories are better positioned to validate the assay, train staff, and connect test results to memory clinics or neurology services. Community practices and rural hospitals may need to send samples to reference labs, adding turnaround time and potential barriers if shipping logistics or contract terms prove complicated. If insurers delay coverage decisions, patients could face out-of-pocket costs that deter testing even when clinically appropriate.
For payers, the calculus extends beyond the price of the assay itself. Confirming amyloid pathology earlier in the disease course may increase the number of patients eligible for disease-modifying therapies, which are expensive and require ongoing monitoring for side effects. At the same time, more accurate diagnosis can prevent misdirected spending on ineffective treatments, repeated imaging, or prolonged diagnostic workups. Whether the plasma test ultimately lowers or raises total costs will depend on how it is used in practice and how closely real-world performance matches trial data.
Balancing promise with caution
The Lumipulse plasma ratio test arrives at a moment when Alzheimer’s care is in flux. New therapies targeting amyloid have heightened the urgency of establishing or ruling out amyloid pathology, while demographic trends point toward rising numbers of older adults at risk for dementia. A blood-based assay that can be ordered in ordinary clinics offers a way to bridge the gap between cutting-edge treatments and everyday practice.
Yet the concurrent recall underscores how fragile confidence in a novel diagnostic can be. Even a limited, technical issue affecting specific lots may prompt some institutions to wait for more data or updated labeling before broad deployment. Transparency from the manufacturer and regulators about any identified root causes, along with clear communication to laboratories about replacement lots, will be central to rebuilding trust where it has been shaken.
In the interim, clinicians are likely to treat the new plasma assay as one piece of a broader puzzle rather than a standalone arbiter of diagnosis. Used thoughtfully, it can help prioritize which patients should undergo more invasive or costly confirmatory tests, inform discussions with families about prognosis, and guide referrals to specialty care. Used indiscriminately, it risks overdiagnosis, anxiety, and potential misalignment with treatment options that still have strict eligibility criteria.
For patients and caregivers, the message is similarly nuanced. A blood test cannot by itself capture the full complexity of memory loss, which may stem from multiple overlapping causes, including vascular disease, depression, medication effects, or other neurodegenerative conditions. But when interpreted in context by clinicians who understand its strengths and limitations, the Lumipulse assay offers a more accessible window into brain pathology than has previously been available outside major centers.
As post-market data accumulate and coverage decisions take shape, the trajectory of this test will serve as a bellwether for future blood-based diagnostics in neurology. If the field can navigate the early recall, clarify reimbursement, and integrate the assay into evidence-based care pathways, the Lumipulse plasma ratio may mark the beginning of a new, more scalable era in Alzheimer’s diagnosis rather than an isolated breakthrough constrained by implementation hurdles.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
